Series date: 
01/01/2023 - 7:00am CST to 12/31/2023 - 11:59pm CST

OBJECTIVES: Upon completion of this activity, the participant should be able to:  (1) Upon completion of this activity, the learners should be able to formulate the best course of Urology Cancer treatment for the patient with the input of the tumor board team, (2) Identify appropriate NCCN guidelines-based care for patients with primary renal/prostate cancer, as well as metastatic disease. 

PLANNER/MODERATOR DISCLOSURE: Scott Webster, MD, was a speaker for Astellas Pharma Inc.

All relevant financial relationships have been mitigated.

ACCREDITATION: The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

DESIGNATION:  The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information, please contact Tarah Brown at [email protected]

 

Series location: 
Baylor Charles A. Sammons Cancer Center - Dallas Campus
3410 Worth Street Ste 580
Dallas, TX 75246
United States

Sessions

Session Date
YYYYMMDD Dallas Urology TB TEMPLATE 01/18/2023 - 7:00am to 8:00am CST
20230215 Dallas Urology TB 02/15/2023 - 7:00am to 8:00am CST
CANCELLED 20230315 Dallas Urology TB 03/15/2023 - 7:00am to 8:00am CDT
20230419 Dallas Urology TB 04/19/2023 - 7:00am to 8:00am CDT
20230517 Dallas Urology TB 05/17/2023 - 7:00am to 8:00am CDT
20230621 Dallas Urology TB 06/21/2023 - 7:00am to 8:00am CDT
20230719 Dallas Urology TB 07/19/2023 - 7:00am to 8:00am CDT
20230816 Dallas Urology TB 08/16/2023 - 7:00am to 8:00am CDT
20230920 Dallas Urology TB 09/20/2023 - 7:00am to 8:00am CDT
20231018 Dallas Urology TB 10/18/2023 - 7:00am to 8:00am CDT

Pages